DEEP SOURCE (00990) launches buyback to demonstrate confidence in transformation.
CStone Pharmaceuticals announced that, on July 21, 2026, it has decided to utilize its repurchase authorization, as well as any future general authorization approved by the shareholders at the company's general meeting for repurchasing shares, to repurchase shares on the open market (share repurchase).
DEEP SOURCE (00990) announced on July 21, 2026, that it has decided to use its buyback authorization, as well as (if applicable) any future general authorizations approved by shareholders at the company's general meeting to repurchase shares on the open market (proposed share buyback).
The company believes that the current trading price of the shares does not reflect their intrinsic value or the actual business prospects of the company, and the proposed share buyback also reflects the company's confidence in its own business development prospects.
Related Articles
US Stock Market Move | Halliburton (HAL.US) fell nearly 6% as Q3 revenue guidance weakened.
US Stock Market Move | Tesla, Inc. (TSLA.US) rises more than 3%, the market expects a year-on-year increase of nearly 30% in Q2 earnings per share.
SUNHO BIO-B(02898): Fan Rongkui terminates his appointment as non-executive director.
US Stock Market Move | Halliburton (HAL.US) fell nearly 6% as Q3 revenue guidance weakened.
US Stock Market Move | Tesla, Inc. (TSLA.US) rises more than 3%, the market expects a year-on-year increase of nearly 30% in Q2 earnings per share.
SUNHO BIO-B(02898): Fan Rongkui terminates his appointment as non-executive director.
RECOMMEND
